Predictors of Atherosclerotic Events in Patients on Haemodialysis: Post hoc analyses from the AURORA Study.

Marit D. Solbu, PhD [1,2,3]; Geir Mjøen, PhD[4]; Patrick B. Mark, PhD[1,5]; Hallvard Holdaas, PhD[6]; Bengt Fellström, PhD[7]; ; Roland E. Schmieder, PhD[8]; Faiez Zannad, PhD[9]; William G. Herrington, MD[10]; Alan Jardine, MD[1,5]

[1]University of Glasgow, Institute of Cardiovascular and Medical Sciences, Glasgow, United Kingdom; [2]Section of Nephrology, University Hospital of North Norway, Tromsø, Norway; [3]Metabolic and Renal Research Group, UiT The Arctic University of Norway, Tromsø, Norway; [4]Department of Nephrology Ullevål, Oslo University Hospital, Oslo, Norway; [5]Queen Elizabeth University Hospital Glasgow, The Renal and Transplant Unit, Glasgow, United Kingdom; [6]Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway; [7]Division of Nephrology, Department of Internal Medicine, Uppsala University Hospital, Uppsala, Sweden. [8]Department of Nephrology and Hypertension, University Hospital, Erlangen-Nürnberg, Germany; [9]Inserm, Clinical Investigation Centre 1433, Université de Lorraine and CHU, Nancy, France; and [10]Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, United Kingdom.

Address for correspondence:

Marit D. Solbu,
Section of Nephrology, Division of Internal Medicine,
University Hospital of North Norway,
N-9038 Tromsø, Norway

Fax: +4777669416
Telephone: +4791864376
E-mail: marit.solbu@unn.no

Running head: Predictors of atherosclerotic disease in Haemodialysis

Word count: 3567 (including abstract, keywords and short summary)

Abstract

Background: Patients on haemodialysis are at high risk for cardiovascular events, but heart failure and sudden death are more common than atherosclerotic events. The AURORA trial was designed to assess the effect of rosuvastatin on myocardial infarction and death from any cardiac cause in 2773 haemodialysis patients. We studied predictors of the atherosclerotic cardiovascular events in AURORA.

Methods: We readjudicated all deaths and presumed myocardial infarctions according to the criteria used in the Study of Heart and Renal Protection (SHARP); these were specifically developed to separate atherosclerotic from non-atherosclerotic cardiovascular events. The readjudicated atherosclerotic endpoint included first event of the following: non-fatal myocardial infarction, fatal coronary heart disease, non-fatal and fatal non-haemorrhagic stroke, coronary revascularisation procedures and death from ischaemic limb disease. Step-wise Cox regression analysis was used to identify the predictors of such events.

Results: During a mean follow-up of 3.2 years, 506 patients experienced the new composite atherosclerotic outcome. Age, male sex, prevalent diabetes, prior cardiovascular disease, weekly dialysis duration, baseline albumin (HR 0.96; 95% CI 0.94-0.99 per g/L increase), high sensitive CRP (HR 1.13; 95% CI 1.04-1.22 per mg/L increase) and oxidised LDL cholesterol (HR 1.09; 95% CI 1.03-1.17 per 10 U/L increase) were selected as significant predictors in the model. Neither LDL cholesterol nor allocation to placebo/rosuvastatin therapy predicted the outcome.

Conclusions: Even with the use of strict criteria for endpoint definition, non-traditional risk factors, but not lipid disturbances, predicted atherosclerotic events in haemodialysis patients.

Keywords: Haemodialysis, Atherosclerosis, Coronary Artery Disease, Statins, Survival analysis, Vascular calcification

Short summary:

In the large randomised controlled trials of statin treatment in dialysis patients, cardiovascular disease has been classified using diverging code rules, and atherosclerotic events have been defined differently. We recadjudicated all fatal events and all events originally classified as non-fatal coronary heart disease in the AURORA trial using the code rules applied in SHARP, and we assessed predictors of atherosclerotic cardiovascular events only. In spite of the strict definition used for atherosclerotic diseases, we found that neither LDL cholesterol, total cholesterol nor randomisation to statin or placebo treatment predicted the new endpoint, whereas non-traditional risk factors such as hypoalbuminaemia, high sensitive CRP and oxidised LDL were significant predictors.

Introduction

Although survival in patients on haemodialysis (HD) has improved during the last two decades [1, 2], adjusted mortality rates are still high [1]. In prevalent dialysis patients, cardiovascular disease (CVD) is the leading cause of death, accounting for approximately 40% of all deaths [1, 2].

The use of strategies to lower low density lipoprotein (LDL) cholesterol, including statins, as prevention against coronary heart disease (CHD) and other atherosclerotic vascular diseases is well-established in the general population [3]. In patients with chronic kidney disease (CKD), however, and particularly in patients on maintenance dialysis, sudden cardiac death and heart failure predominate [4-6], and traditional risk factors for atherosclerosis, such as hyperlipidaemia, appear to play a less prominent role. Instead, non-traditional risk factors including uraemic toxins, markers of mineral bone disorder and vascular calcification, inflammation, oxidative stress and fluid overload [6] have been associated with increased CVD risk in this population. Nevertheless, traditional cardiovascular risk factors (e.g. hypertension and dyslipidaemia), as well as atherosclerotic diseases, are commonly observed in haemodialysis (HD) patients. [7, 8].

Two large randomised controlled trials, the A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA) and Die Deutsche Diabetes Dialyse Studie (4D), were designed to test whether statin treatment could improve cardiovascular morbidity and mortality in HD patients [9, 10]. Both failed to demonstrate a significant benefit of LDL-lowering therapy on the primary vascular end-points. Although the lack of interaction between treatment allocation and dialysis status at baseline (yes/no) in the Study of Heart and Renal Protection (SHARP) contradicted a subgroup difference, no significant treatment effect of simvastatin plus ezetimibe was observed when the dialysis subgroup was considered in isolation [11]. In AURORA, which so far is the largest randomised statin trial conducted solely in patients on dialysis, the primary outcome was a composite endpoint of atherosclerotic and non-atherosclerotic cardiovascular events. The reported percentage of deaths attributable to CHD was

three times the percentage reported in 4D and four times the reported incident rate in the dialysis subgroup in SHARP [11]. Although inclusion criteria and treatment strategy varied slightly between the three trials (Table 1), the dissimilarities in outcome incidence have been attributed to differences in coding rules used to ascribe deaths to CHD in these trials.

In order to separate atherosclerotic from non-atherosclerotic cardiovascular events in AURORA, we readjudicated all fatal events and non-fatal coronary events according to criteria specifically developed to separate atherosclerotic from non-atherosclerotic cardiovascular events in kidney disease, i.e. the same criteria that were used in SHARP. The aim of the present study was to assess predictors of a combined atherosclerotic cardiovascular endpoint similar to the main outcome in SHARP.

Subjects and Methods

Study Cohort and the Design of the AURORA Trial

The design, baseline data and main results of the AURORA trial have been published previously [9, 12]. In short, in 2003-2004, 2,773 male and female prevalent HD patients (treated for ≥3 months), aged 50-80 years, from 280 centres in 25 countries across the world were randomised 1:1 to receive either rosuvastatin 10 mg per day or placebo. The mean follow-up time was 3.2 years. The primary composite endpoint was time to a major cardiovascular event, defined as non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes. A sudden, unexpected death was attributed to CHD (definite or suspected) if there was inadequate information to ascribe a non-cardiovascular cause. All events were adjudicated by an independent endpoint committee blinded to treatment allocation. The study (clinicaltrials.gov identifier number NCT00240331) was conducted in accordance with the ethical principles of the Declaration of Helsinki, the Good Clinical Practice

guidelines of the International Conference of Harmonisation, and local regulatory requirements at all participating centres.

Readjudication of fatal and non-fatal events

In 2014 and 2015, all fatal events and all events originally classified as definite or suspected non-fatal myocardial infarctions were readjudicated according to criteria identical to those used in SHARP [11]. Non-fatal and fatal coronary events were classified as definite, probable or possible. A death was attributed to acute CHD if diagnosed by post-mortem examination and no other probable cause of death was revealed, or on the basis of clinical criteria. Typical (chest pain) or atypical (pulmonary oedema, syncope or shock) coronary symptoms were a prerequisite for the clinical diagnosis of all CHD, and ECG and myocardial biomarkers were reviewed according to strict criteria. In order to be attributed to CHD, death must have occurred within 28 days of the coronary event and no other cause of death must have been recorded. A sudden, unexpected death was not assigned a coronary cause unless supported by ECG, biomarkers or autopsy. Using the overriding principles set out by the International Statistical Classification of Disease and Related Health Problems 10th Revision (ICD-10), "the disease or injury which initiated the chain of morbid events leading directly to death" was recorded as the cause of death.

The readjudications were completed by two experienced clinicians who were blinded to treatment allocation, other exposure data and the original event adjudication. In case of doubts, the event was discussed by two consultants. Also, random cases were evaluated by both consultants to ensure coherent adjudication.

The new composite atherosclerotic endpoint comprised first event of the following: definite, probable or possible non-fatal myocardial infarction or fatal CHD, coronary revascularisation

procedures and non-fatal or fatal non-haemorrhagic or unspecified stroke. In addition, death from peripheral artery disease (PAD) was included in the endpoint.

Statistical analyses

Originally, 805 primary events were required for 87% power to reveal a 19.5% lower incidence rate in the AURORA treatment group [9]. The readjudication process resulted in a considerably lower number of events. Thus, the statistical power to assess the treatment effect of rosuvastatin on the new endpoint was reduced. However, we chose to run the intention-to-treat analysis, using an unadjusted Cox regression model and producing a Kaplan-Meier survival curve. All other analyses in the present study were done in the entire AUROA cohort with no regards to treatment allocation.

Data are presented as mean (standard deviation [SD]) or number (%) as appropriate. Differences in baseline risk factors between patients who did or did not experience the new composite endpoint were assessed using two-tailed independent samples t-tests or chi square tests, as appropriate.

Crude incidence rates of each atherosclerotic endpoint were calculated as events per 1000 person years at risk.

Cox proportional hazard regression analyses were run to assess the impact of baseline risk factors on the composite atherosclerotic endpoint. We calculated the univariate hazard ratios (HR) and 95% confidence intervals (CI) for the following potential predictors: demographics (sex, age, geographic region) comorbidity (diabetes, history of CVD, history of CHD), lipids (total cholesterol, LDL cholesterol, high density lipoprotein [HDL] cholesterol, triglycerides), other traditional risk factors (body weight and height, body mass index, current smoking, systolic and diastolic blood pressure, pulse pressure), dialysis specific risk factors (HD vintage, weekly duration of HD treatment, dialysis quality measured as Kt/V), other non-traditional or uraemia-specific risk factors and inflammation markers (phosphate, calcium, albumin, haemoglobin, haematocrit and high sensitive C-reactive

protein [hsCRP]). Oxidised LDL cholesterol and apolipoprotein (Apo) B/Apo A1ratio may be characterised as markers of lipid disturbances or inflammation and were also assessed as predictors. Finally, current medication use (beta-blockers, inhibitors of the renin-angiotensin-system, sevelamer) and randomised treatment allocation (rosuvastatin vs. placebo) were entered into univariate Cox models.

All variables with a $P<0.1$ for univariate association with the atherosclerotic endpoint were included in a backwards step-wise Cox regression model to obtain the independent risk factors.

The same procedure was repeated for each subgroup of events: CHD (fatal or non-fatal myocardial infarction and/or coronary revascularisation), non-haemorrhagic or unspecified stroke (fatal or non-fatal) and death from PAD.

Non-linear associations with the main endpoint were assessed in univariate Cox regression models for each predictor categorised into quartiles.

The proportional hazard assumption for each Cox model was checked using a global test of scaled Schoenfeld residuals against time. Analyses were run using IBM SPSS Statistics Software version 20 (IBM Corp., Armonk, NY) and Stata Statistical Software 11 (StataCorp LP, TX). Two-sided P values <0.05 were considered statistically significant.

Results

Baseline Risk Factors

Baseline characteristics for patients according to whether they did or did not experience the new composite endpoint are presented in Table 2. The 506 patients who had at least one atherosclerotic event during follow-up were more frequently men, older and had a higher prevalence of diabetes and previous CVD at baseline than the 2267 patients with no reported atherosclerotic event.

However, lipid values other than HDL cholesterol, systolic blood pressure and frequency of current smoking did not differ significantly between the two groups. The event group had significantly lower albumin and higher levels of markers of inflammation and oxidative stress including hsCRP, oxidised LDL and Apo B/Apo A1 ratio. These patients also had longer HD treatment per week, whereas dialysis vintage and quality were similar. Patients from Western Europe were over-represented in the endpoint-group compared to the group without atherosclerotic events, whereas the opposite was found for patients from South-America.

The Combined Atherosclerotic Endpoint and Predictor Assessment

There were 506 patients who experienced at least one atherosclerotic event. Some patients had more than one non-fatal event. The numbers of first event within each sub-group of atherosclerotic disease, as well as crude incidence rates, are given in Table 3. The composite endpoint included 120 non-fatal and 78 fatal CHD events, 180 coronary revascularisation procedures, 71 non-fatal and 28 fatal non-haemorrhagic and unspecified strokes and 29 deaths due to PAD.

There was no significant effect of allocation category (rosuvastatin or placebo) on the new endpoint (Figure 1 and Table 4).

The univariate and multivariable associations between traditional and non-traditional risk factors and the readjudicated atherosclerotic endpoint are displayed in Table 4. LDL cholesterol was not significantly associated with the endpoint in univariate analyses. Thus, neither LDL cholesterol nor treatment allocation were included in the multivariable model. Significant association with the composite endpoint was found for HDL cholesterol, Apo B/Apo A1 ratio and oxidised LDL in univariate analyses. In multivariable analysis age, male sex, diabetes and prevalent CVD significantly predicted the atherosclerotic endpoint, whereas no parameter reflecting hyperlipidaemia were independent predictors. Hypoalbuminaemia, increased hsCRP and oxidised LDL cholesterol were

independent non-traditional predictors of the combined endpoint. Patients from South-America had a lower HR for the combined endpoint than patients from other geographical regions. A non-linear association was found between dialysis vintage and the atherosclerotic endpoint, with dialysis vintage in the second quartile (1.0 - 2.3 years) predicting significantly reduced risk of events compared to the fourth quartile (>4.4 years), and a non-significant trend towards higher event risk in the first quartile. In multivariable analysis with the categorised dialysis vintage variable, estimates were essentially unchanged, apart from weekly HD duration loosing and phosphate gaining statistical significance (data not shown). No other variables exhibited a non-linear association with the endpoint. Collinearity/multicollinearity did not affect any of the multivariable analyses.

Predictors of CHD, Ischaemic Stroke and Death from PAD

During follow-up, 384 persons had at least one non-fatal or fatal myocardial infarction and/or underwent coronary revascularisation (Tables 3 and 5). In univariate Cox regression analyses, several traditional (age, sex, previous CHD and CVD, diabetes, body weight and height, low diastolic blood pressure and low HDL cholesterol) and non-traditional (dialysis duration, hsCRP and low albumin) risk factors predicted CHD. An elevated Apo B/Apo A1 ratio was also associated with this endpoint (Table 5). LDL cholesterol was not a significant predictor of CHD (HR per mmol/L increase 1.03 (95% CI 0.92 – 1.15; P=0.59), and neither was randomisation category (P=0.96). Both univariate and multivariable analyses of predictors for CHD mimicked the results for the combined atherosclerotic endpoint, but Apo B/Apo A1 ratio remained significantly associated with CHD in the fully adjusted models. Furthermore, elevated serum phosphate independently predicted CHD.

There were only 116 patients who had at least one episode of non-haemorrhagic or unspecified stroke (non-fatal or fatal), and 50 patients died from PAD, limiting the power to study these outcomes in isolation. Age and hypoalbuminaemia independently predicted stroke in the

multivariable Cox regression analysis (Table 6). High serum phosphate strongly predicted death from PAD, as did prevalent diabetes, previous CVD, hypoalbuminaemia, higher LDL cholesterol and higher hsCRP (Table 7).

Discussion

In a large cohort of prevalent HD patients, we found that elevated LDL cholesterol was not selected as a predictor of the new composite atherosclerotic endpoint, despite a strict definition of atherosclerosis according to the SHARP criteria. Traditional risk factors were mainly non-modifiable (higher age, sex, diabetes and a history of CVD). Moreover, the model identified non-traditional risk factors, including hypoalbuminaemia and biomarkers of oxidative stress and inflammation, as significant predictors of atherosclerotic events, similar to previously published predictors of all major cardiovascular events in AURORA [13].

In the general population, atherosclerosis dominates as the pathological substrate for CVD. CHD is the major cause of cardiovascular morbidity and mortality, and the Framingham risk score is a validated tool for risk prediction [14]. The same tool has been evaluated to be less useful in patients with CKD not on dialysis [15]. In patients on chronic HD, cardiac diseases such as heart failure [16, 17] and sudden death [4], surpass the classic atherosclerotic disorders. Nevertheless, coronary pathology is common in advanced stages of CKD [5, 8, 17, 18], and atherosclerotic diseases infer a worse prognosis in this patient group than in non-CKD patients [19, 20]. Therefore, assessment of predictors of this subset of CVD is of considerable importance also in patients on maintenance dialysis.

Available data about predictors of atherosclerotic CVD in dialysis patients is limited, with studies often considering cardiovascular events overall [16, 21, 22] or relying on less accurate death registry reports [23, 24]. Furthermore, there are no agreed criteria on which to distinguish atherosclerotic

from non-atherosclerotic CVD in trials [9-11, 25]. Partly, these variations reflect challenges in diagnosing atherosclerotic events in HD patients [26]. For example, dialysis patients with acute coronary syndrome often have atypical symptoms [26, 27], ST elevations are observed less frequently [26, 28], and myocardial biomarkers have low sensitivity and specificity to diagnose the disease [29].

Despite the effort to separate non-atherosclerotic from atherosclerotic events that was made in the present study, there may be a substantial overlap and no clear-cut differences between these diseases in prevalent dialysis patients. Vascular calcification, which is associated with CVD and mortality, is common. [30, 31]. Coronary atherosclerotic lesions are characterised by marked calcifications consisting of hydroxylapatite and calcium-phosphate, increased media thickness and reduced lumen area [32]. Phosphate is among the promoters of progressive calcification and a strong predictor of adverse outcome in dialysis patients [33]. In our study, phosphate did not predict the composite endpoint, but independently predicted CHD and death from PAD. This is in agreement with the reported discoveries of calcium-phosphate rich coronary plaques that may differ from atherosclerotic plaques in non-CKD patients. There is substantial evidence suggesting that risk scoring as well as preventive interventions in this patient group cannot be adopted directly from guidelines developed for other risk groups [34, 35].

The fact that oxidised LDL cholesterol was significantly associated with atherosclerotic events is of interest. Oxidatively modified LDL cholesterol particles exhibit proinflammatory and proatherogenic effects in vessel walls, including chemoattractant, cytotoxic and cytokine stimulatory effects. Monocytes have effective uptake mechanisms for these modified LDL cholesterol molecules, facilitating the formation of foam cells [36]. Conflicting data have been published regarding levels of oxidised LDL in dialysis patients. Whereas one study reports nearly 10 times higher levels [37], others have reported no difference [38] or even lower values [39] in dialysis patients compared with healthy individuals. Furthermore, whether oxidised LDL cholesterol primarily is a marker of lipid

disturbances or indicates oxidative stress, has not yet been agreed upon [39, 40]. Nevertheless, in our study LDL cholesterol was associated with death from PAD, and Apo B/Apo A1 ratio predicted CHD. A recent meta-analysis that included placebo controlled statin trials in patients on maintenance dialysis, confirmed a hsCRP lowering effect from statin treatment [41]. A *post hoc* analysis from the 4D study demonstrated significant risk reduction by atorvastatin in HD patients with pre-treatment LDL cholesterol level in the highest quartile. At baseline, this group also had lower serum albumin and higher hsCRP [42]. Therefore, it cannot be ruled out that both an atherogenic lipoprotein profile and chronic inflammation are risk factors that may be available for intervention in a subset of prevalent HD patients.

The AURORA cohort consisted of prevalent HD patients who had been on maintenance dialysis for median 28.0 months [12]. Dialysis vintage has been shown to predict progression of vascular calcification [43-45], whereas traditional risk factors, including LDL cholesterol, do not increase with increasing duration of HD treatment [46]. One may speculate that "traditional" atherosclerosis associated with traditional risk factors becomes less common, whereas vascular calcification, not readily accessible for established preventive measures, becomes increasingly important with increasing time on HD.

We found a significantly lower risk of CHD and atherosclerotic events in patients dialysed in South America compared to the other geographic regions. This phenomenon probably reflects differences in diagnosis and reporting of CHD in this region, as well as a higher incidence of other causes of death during the study period.

The incidence rate of ischaemic stroke is high in HD patients [47, 48]. Older age and diabetes have consistently been reported to be associated with ischaemic stroke in HD cohorts [47, 48]. In the present study, only high age and hypoalbuminaemia were selected as predictors, but the number of strokes was low, and the results should be interpreted with caution.

Important strengths of our study were the large cohort of well-characterised, prevalent HD patients from 25 different countries worldwide. Furthermore, each event was readjudicated by clinicians according to validated criteria. However, residual confounding due to measurement error, unmeasured risk factors and the lack of adjustment for time varying covariates during follow-up constitute important limitations. The observational study design, and in particular the use of statistical models that selected predictors in an automated fashion, precludes causal inferences, and the lack of associations between traditional risk factors and the atherosclerotic endpoint, should be interpreted with caution. As discussed above, a clear separation between atherosclerotic and non-atherosclerotic events is difficult in patients on dialysis, and misclassifications may have interfered with our results. Therefore, we cannot exclude the possibility that a clinically significant association between hyperlipidaemia and a subset of atherosclerotic events may exist in prevalent HD patients. Moreover, our results may not be generalizable to younger dialysis populations with shorter HD vintage.

In conclusion, this *post hoc* analysis from the AURORA trial confirmed that modifiable traditional risk factors including lipid disturbances did not predict atherosclerotic cardiovascular events in prevalent HD patients. The events were adjudicated with the use of strict and validated criteria. Markers of inflammation and oxidative stress were significant predictors, and future studies should further evaluate the relevance of these markers and whether they may be targets for novel treatment strategies in patients on dialysis.

Conflict of Interest Statement

None of the authors declares any conflict of interest.

Acknowledgements

The AURORA trial was sponsored by AstraZeneca. The authors acknowledge Professor Colin Baigent and Dr. Martin Landray at The Clinical Trial Service Unit, University of Oxford (UK), for providing us with the SHARP event adjudication manual.

References

1. United States Renal Data System. 2014 USRD Annual Data Report. Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2014
2. Steenkamp R, Rao A, Roderick P. UK Renal Registry 17th Annual Report: Chapter 5 Survival and Cause of Death in UK Adult Patients on Renal Replacement Therapy in 2013: National and Centre-specific Analyses. UK Renal Registry, Bristol, UK, 2014
3. Baigent C, Keech A, Kearney PM, *et al*. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
4. Zipes DP, Camm AJ, Borggrefe M*, et al.* ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006;48:e247-e346
5. Cheung AK, Sarnak MJ, Yan G*, et al.* Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int 2004;65:2380-2389
6. Ortiz A, Covic A, Fliser D*, et al.* Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014;383:1831-1843
7. Iwasaki M, Joki N, Tanaka Y*, et al.* Declining Prevalence of Coronary Artery Disease in Incident Dialysis Patients Over the Past Two Decades. J Atheroscler Thromb 2014;21:593-604
8. Charytan D, Kuntz RE, Mauri L*, et al.* Distribution of Coronary Artery Disease and Relation to Mortality in Asymptomatic Hemodialysis Patients. Am J Kidney Dis 2007;49:409-416
9. Fellström BC, Jardine AG, Schmieder RE*, et al.* Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. N Engl J Med 2009;360:1395-1407
10. Wanner C, Krane V, März W*, et al.* Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. N Engl J Med 2005;353:238-248
11. Baigent C, Landray MJ, Reith C*, et al.* The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet 2011;377:2181-2192
12. Fellström B, Holdaas H, Jardine AG*, et al.* Effect of Rosuvastatin on Outcomes in Chronic Haemodialysis Patients: Baseline Data from the AURORA Study. Kidney Blood Press Res 2007;30:314-322
13. Schneider A, Jardine AG, Schneider MP*, et al.* Determinants of cardiovascular risk in haemodialysis patients: post hoc analyses of the AURORA study. Am J Nephrol 2013;37:144-151

14. D'Agostino RB, Sr., Grundy S, Sullivan LM*, et al.* Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-187
15. Weiner DE, Tighiouart H, Elsayed EF*, et al.* The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007;50:217-224
16. Harnett JD, Foley RN, Kent GM*, et al.* Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47:884-890
17. Chertow GM, Correa-Rotter R, Block GA*, et al.* Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrol Dial Transpl 2012;27:2872-2879
18. Group FT, Chertow GM, Levin NW*, et al.* In-Center Hemodialysis Six Times per Week versus Three Times per Week. N Engl J Med 2010;363:2287-2300
19. Hanna EB, Chen AY, Roe MT*, et al.* Characteristics and In-Hospital Outcomes of Patients With Non–ST-Segment Elevation Myocardial Infarction and Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol Intv 2011;4:1002-1008
20. Saltzman AJ, Stone GW, Claessen BE*, et al.* Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. J Am Coll Cardiol Intv 2011;4:1011-1019
21. de Jager DJ, Grootendorst DC, Jager KJ*, et al.* CArdiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009;302:1782-1789
22. Kilpatrick RD, McAllister CJ, Kovesdy CP*, et al.* Association between Serum Lipids and Survival in Hemodialysis Patients and Impact of Race. J Am Soc Nephrol 2007;18:293-303
23. Herzog CA, Strief JW, Collins AJ*, et al.* Cause-specific mortality of dialysis patients after coronary revascularization: why don't dialysis patients have better survival after coronary intervention? Nephrol Dial Transpl 2008;23:2629-2633
24. Rampatige R, Mikkelsen L, Hernandez B*, et al.* Systematic review of statistics on causes of deaths in hospitals: strengthening the evidence for policy-makers. Bull World Health Organ 2014;92:807-816
25. Chertow GM, Block G*,* Correa-Rotter R*, et al.* Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. N Engl J Med 2012;367:2482-2494
26. Herzog CA, Littrell K, Arko C*, et al.* Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 2007;116:1465-1472
27. Szummer K, Lundman P, Jacobson SH*, et al.* Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med 2010;268:40-49
28. Gurm HS, Gore JM, Anderson Jr FA*, et al.* Comparison of Acute Coronary Syndrome in Patients Receiving Versus Not Receiving Chronic Dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry). Am J Cardiol 2012;109:19-25
29. Stacy SR, Suarez-Cuervo C, Berger Z*, et al.* Role of Troponin in Patients With Chronic Kidney Disease and Suspected Acute Coronary SyndromeA Systematic ReviewRole of Troponin in Patients With CKD and Suspected Acute Coronary Syndrome. Ann Int Med 2014;161:502-512
30. Huybrechts KF, Caro JJ, London GM. Modeling the implications of changes in vascular calcification in patients on hemodialysis. Kidney Int 2005;67:1532-1538
31. Block GA, Raggi P, Bellasi A*, et al.* Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-441
32. Schwarz U, Buzello M, Ritz E*, et al.* Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000;15:218-223
33. Floege J, Kim J, Ireland E*, et al.* Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011;26:1948-1955

34. Floege J, Gillespie IA, Kronenberg F*, et al.* Development and validation of a predictive mortality risk score from a European hemodialysis cohort. Kidney Int 2015;87:996-1008
35. Palmer SC, Craig JC, Navaneethan SD*, et al.* Benefits and Harms of Statin Therapy for Persons With Chronic Kidney DiseaseA Systematic Review and Meta-analysis. Ann Int Med 2012;157:263-275
36. Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J Lipid Res 2009;50 Suppl:S376-381
37. Samouilidou EC, Karpouza AP, Kostopoulos V*, et al.* Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis. Ren Fail 2012;34:160-164
38. Johnson-Davis KL, Fernelius C, Eliason NB*, et al.* Blood Enzymes and Oxidative Stress in Chronic Kidney Disease: A Cross Sectional Study. Ann Clin Lab Sci 2011;41:331-339
39. Pawlak K, Mysliwiec M, Pawlak D. Oxidized low-density lipoprotein (oxLDL) plasma levels and oxLDL to LDL ratio — Are they real oxidative stress markers in dialyzed patients? Life Sciences 2013;92:253-258
40. An WS, Kim SE, Kim KH*, et al.* Associations between oxidized LDL to LDL ratio, HDL and vascular calcification in the feet of hemodialysis patients. J Korean Med Sci 2009;24 Suppl:S115-120
41. Sun L, Zou L, Chen M*, et al.* Meta-analysis of statin therapy in maintenance dialysis patients. Ren Fail 2015;37:1149-1156
42. März W, Genser B, Drechsler C*, et al.* Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis. Clin J Am Soc Nephrol 2011;6:1316-1325
43. Yazbek DC, de Carvalho AB, Barros CS*, et al.* Cardiovascular Disease in Early Kidney Transplantation: Comparison Between Living and Deceased Donor Recipients. Transplant Proc 2012;44:3001-3006
44. Kim HG, Song SW, Kim TY*, et al.* Risk factors for progression of aortic arch calcification in patients on maintenance hemodialysis and peritoneal dialysis. Hemodial Int 2011;15:460-467
45. Roberts WC, Taylor MA, Shirani J. Cardiac findings at necropsy in patients with chronic kidney disease maintained on chronic hemodialysis. Medicine 2012;91:165-178
46. Pruijm M, Schmidtko J, Aho A*, et al.* High Prevalence of Anti-Apolipoprotein/A-1 Autoantibodies in Maintenance Hemodialysis and Association With Dialysis Vintage. Ther Apher Dial 2012;16:588-594
47. Herrington W, Haynes R, Staplin N*, et al.* Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. Semin Dial 2015;28:35-47
48. Findlay MD, Thomson PC, Fulton RL*, et al.* Risk Factors of Ischemic Stroke and Subsequent Outcome in Patients Receiving Hemodialysis. Stroke 2015;46:2477-81

Table 1. Study design of the main trials assessing the effect of LDL cholesterol lowering agents in patients on dialysis.

	Inclusion criteria	Treatment strategy	Pre-defined endpoints
AURORA	LDL cholesterol of any value Men and women aged 50-80 years ESRD and chronic haemodialysis for ≥3 months	Rosuvastatin 10 mg vs. placebo	Primary endpoint Time to MACE (non-fatal myocardial infarction, non-fatal stroke, death from a cardiovascular cause) Secondary endpoints All-cause mortality Cardiovascular event-free survival Death from a cardiovascular cause Death from a non-cardiovascular cause Coronary or peripheral revascularisation Procedure for stenosis or thrombosis of the vascular access*
SHARP	LDL cholesterol of any value Men and women ≥40 years History of CKD Blood creatinine ≥150 µmol/L in men or ≥130 µmol/L in women On dialysis (haemodialysis or peritoneal dialysis)	Ezetimibe 10 mg/simvastatin 20 mg vs. placebo	Primary endpoint Time to major atherosclerotic event (non-fatal myocardial infarction, coronary death, non-haemorrhagic stroke, arterial revascularisation procedure) Secondary endpoints Each separate component of the primary endpoint Major vascular event (primary endpoint,

			non-coronary cardiac death, haemorrhagic stroke) Commencement of chronic dialysis or kidney transplantation
4D	Fasting LDL cholesterol ≥2.1 mmol/L and ≤4.9 mmol/L Men and women aged 18-80 years Chronic haemodialysis for ≤2 years	Atorvastatin 20 mg vs. placebo	Primary endpoint Time to MACE (fatal myocardial infarction, sudden death, death from congestive heart failure, death from diagnostic or therapeutic procedure due to coronary artery disease, death from another coronary cause, non-fatal myocardial infarction, non-fatal or fatal stroke) Secondary endpoints All-cause mortality Cardiovascular event (cardiovascular death, myocardial infarction, coronary intervention procedure) Cerebrovascular event (stroke, transient ischaemic attack) Death from non-cardiovascular causes stratified by cause Changes in lipid levels relative to baseline

LDL: low density lipoprotein. ESRD: End stage renal disease. MACE: Major adverse cardiac event. CKD: chronic kidney disease. *Arteriovenous fistula or graft used for chronic haemodialysis

Table 2. Baseline characteristics of the patients who did and did not experience the combined atherosclerotic endpoint during follow-up.

	Patients with endpoint (n=506)		Patients without endpoint (n=2267)		P-value
Sex, male, n (%)	353	(69.8)	1370	(60.4)	<0.001
Age, years	66.6	±8.5	63.7	±8.6	<0.001
Randomised to rosuvastatin, n (%)	253	(50.0)	1136	(50.0)	0.96
Region, n (%)					<0.001
Western Europe	308	(60.9)	1108	(48.9)	
Eastern Europe	107	(21.1)	480	(21.2)	
Asia	10	(2.0)	72	(3.2)	
South-America	23	(4.5)	323	(14.2)	
Other	58	(11.4)	284	(12.5)	
Systolic blood pressure, mm Hg	136	±25	137	±24	0.23
Diastolic blood pressure, mm Hg	74	±13	76	±13	<0.001
Height, cm	167.9	±9.4	166.7	±9.8	0.014
Weight, kg	72.6	±14.4	70.5	±15.7	0.004
Body mass index, kg/m^2	25.7	±4.7	25.3	±5.0	0.11
Current smoking, n (%)	83	(16.4)	346	(15.3)	0.52
Previous coronary heart disease, n (%)	355	(70.2)	1069	(47.2)	<0.001
Previous cardiovascular disease, n (%)	299	(59.1)	806	(35.6)	<0.001
Diabetes, n (%)	182	(36.0)	549	(24.2)	<0.001
Cholesterol, mmol/L	4.60	±1.12	4.52	±1.09	0.17
LDL cholesterol, mmol/L	2.63	±0.91	2.56	±0.89	0.13
HDL cholesterol, mmol/L	1.13	±0.37	1.17	±0.40	0.043
Triglycerides, mmol/L	1.82	±1.11	1.74	±1.07	0.16
Oxidised LDL cholesterol, U/L	36.0	±15.9	33.8	±13.2	0.004
Apolipoprotein B /Apolipoprotein A1 ratio	0.73	±0.26	0.69	±0.25	0.001

Beta blocker, n (%)	206	(40.7)	826	(36.6)	0.09
ACEi or ARB, n (%)	194	(38.3)	826	(36.6)	0.47
Dialysis vintage, years	3.48	±3.82	3.50	±3.86	0.90
Dialysis time per week, hours	12.1	±1.6	11.8	±1.8	<0.001
Kt/V midweek session	1.20	±0.33	1.20	±0.29	0.68
Phosphate, mmol/L	1.82	±0.54	1.79	±0.55	0.25
Calcium, mmol/L	2.33	±0.20	2.34	±0.22	0.39
Haemoglobin, g/dL	11.8	±1.47	11.6	±1.62	0.021
Albumin, g/dL	39.2	±3.2	39.8	±3.5	<0.001
High sensitive C-reactive protein, mg/L	1.15	±1.18	0.97	±1.15	0.001
Sevelamer, n (%)	84	(16.6)	422	(18.7)	0.27

Values are given as mean (standard deviation) or n (%) as appropriate. LDL: low densitiy lipoprotein. HDL: high density lipoprotein. ACEi: angiotensin converting enzyme inhibitor. ARB: angiotensin II receptor blocker.

Table 3. Subgroups of atherosclerotic diseases; number of events, follow-up time and crude incidence rates. Some patients had several non-fatal events. First event within each diagnosis subgroup has been counted.

	No. of events	Follow-up time, months	No. of events per 1000 patient years (95% confidence interval)	
Combined atherosclerotic outcome	506	100 891	61.0	(55.7-66.3)
Coronary heart disease				
Non-fatal myocardial infarction	123	104 677	14.1	(11.6-16.6)
Fatal myocardial infarction	108	113 390	11.4	(9.3-13.6)
Coronary revascularisation	203	109 034	22.3	(19.3-25.4)
Ischaemic stroke				
Non-fatal ischaemic stroke	85	105 659	9.7	(7.6-11.7)
Fatal ischaemic stroke	33	113 390	3.5	(2.3-4.7)
Death from peripheral atherosclerotic disease	50	113 390	5.3	(3.8-6.8)

Table 4. Univariate and multivariable adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for the combined, readjudicated atherosclerotic endpoint (506 events).

		Univariate models			Multivariable model		
		HR	95% CI	P value	HR	95% CI	P value
Sex, male		1.46	(1.21 - 1.77)	<0.001	1.49	(1.21 - 1.83)	<0.001
Age, per 5 years		1.24	(1.18 - 1.31)	<0.001	1.15	(1.09 - 1.22)	<0.001
Region				<0.001			0.023
	Western Europe	1.30	(0.99 - 1.73)	0.064	1.27	(0.95 -1.71)	0.11
	Eastern Europe	1.12	0.81 - 1.54)	0.50	1.23	(0.88 - 1.71)	0.23
	Asia	0.65	(0.33 - 1.27)	0.21	0.98	(0.49 - 1.96)	0.96
	South-America	0.46	(0.28 - 0.74)	0.001	0.63	(0.38 - 1.04)	0.072
	Other	Ref.			Ref.		
Allocation rosuvastatin vs. placebo, y/n		1.00	(0.84 - 1.19)	0.97			
Systolic blood pressure, per 10 mm Hg		0.99	(0.95 - 1.02)	0.53			
Diastolic blood pressure, per 5 mm Hg		0.94	(0.91 - 0.97)	<0.001			
Pulse pressure, per 5 mm Hg		1.02	(0.99 - 1.04)	0.14			
Body weight, per 5 kg		1.03	(1.00 - 1.06)	0.056			
Body height, per 5 cm		1.05	(1.00 - 1.09)	0.062			
Body mass index, per kg/m^2		1.01	(0.99 - 1.03)	0.29			
Current smoking, y/n		1.09	(0.86 - 1.38)	0.48			
Previous coronary heart disease, y/n		2.74	(2.26 - 3.32)	<0.001			
Previous cardiovascular disease, y/n		2.63	(2.20 - 3.14)	<0.001	1.93	(1.59 - 2.34)	<0.001
Diabetes, y/n		1.93	(1.61 - 2.32)	<0.001	1.76	(1.45 - 2.14)	<0.001
Cholesterol, per mmol/L		1.01	(0.93 - 1.09)	0.82			
LDL cholesterol, per mmol/L		1.03	(0.93 - 1.13)	0.58			
HDL cholesterol, per mmol/L		0.76	(0.60 - 0.96)	0.023			
Triglycerides, per mmol/L		1.03	(0.95 - 1.11)	0.51			
Oxidised LDL cholesterol, per 10 U/L		1.07	(1.01 - 1.14)	0.017	1.09	(1.03 - 1.17)	0.006

Apolipoprotein B /Apolipoprotein A1 ratio, per unit	1.77	(1.28 - 2.45)	0.001			
Beta blocker, y/n	1.14	(0.95 - 1.36)	0.16			
ACEi or ARB, y/n	1.07	(0.90 - 1.28)	0.44			
Dialysis vintage, per year	1.00	(0.98 - 1.02)	0.96			
Dialysis time per week, per hour	1.05	(1.01 - 1.11)	0.031	1.07	(1.01 - 1.12)	0.018
Kt/V midweek session, per unit	0.85	(0.62 - 1.16)	0.29			
Phosphate, per mmol/L	1.14	(0.97 - 1.34)	0.11			
Calcium, per mmol/L	0.80	(0.53 - 1.20)	0.27			
Haematocrit, per %	2.95	(0.46 - 18.8)	0.25			
Haemoglobin, per g/dL	1.03	(0.98 - 1.09)	0.26			
Albumin, per g/L	0.93	(0.91 - 0.95)	<0.001	0.96	(0.94 - 0.99)	0.008
High sensitive C-reactive protein, per mg/L	1.19	(1.11 - 1.27)	<0.001	1.13	(1.04 - 1.22)	0.002
Sevelamer, y/n	0.84	(0.67 - 1.07)	0.16			

LDL: low densitiy lipoprotein. HDL: high density lipoprotein. ACEi: angiotensin converting enzyme inhibitor. ARB: angiotensin II receptor blocker. The significant predictors assessed by a stepwise multivariable Cox regression analysis (which originally included all variables with P<0.1 in univariate analysis) are listed.

Table 5. Univariate and multivariable adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for coronary heart disease (fatal or non-fatal myocardial infarction or coronary revascularisation; 384 events).

	Univariate models			Multivariable model		
	HR	95% CI	P value	HR	95% CI	P value
Sex, male	1.79	(1.43 - 2.25)	<0.001	1.80	(1.41 - 2.30)	<0.001
Age, per 5 years	1.22	(1.15 - 1.29)	<0.001	1.13	(1.06 - 1.20)	<0.001
Region			<0.001			0.002
Western Europe	1.17	(0.86 - 1.59)	0.32	1.18	(0.86 - 1.62)	0.30
Eastern Europe	0.99	(0.70 - 1.42)	0.97	1.12	(0.78 - 1.62)	0.53
Asia	0.77	(0.39 - 1.52)	0.45	1.00	(0.49 - 2.03)	0.99
South-America	0.21	(0.10 - 0.43)	<0.001	0.28	(0.14 - 0.59)	0.001
Other	Ref.					
Allocation rosuvastatin vs. placebo, y/n	1.01	(0.82 - 1.23)	0.96			
Systolic blood pressure, per 10 mm Hg	0.97	(0.93 - 1.02)	0.24			
Diastolic blood pressure, per 5 mm Hg	0.92	(0.88 - 0.96)	<0.001	0.96	(0.92 - 1.00)	0.042
Pulse pressure, per 5 mm Hg	1.02	(0.99 - 1.05)	0.21			
Body weight, per 5 kg	1.04	(1.01 - 1.07)	0.028			
Body height, per 5 cm	1.06	(1.01 - 1.12)	0.029			
Body mass index, per kg/m^2	1.01	(0.99 - 1.03)	0.25			
Current smoking, y/n	1.13	(0.87 - 1.48)	0.36			
Previous coronary heart disease, y/n	3.10	(2.47 - 3.88)	<0.001	1.70	(1.10 - 2.64)	0.017
Previous cardiovascular disease, y/n	2.83	(2.31 - 3.48)	<0.001			
Diabetes, y/n	1.92	(1.56 - 2.36)	<0.001	1.46	(1.11 - 1.91)	0.007
Cholesterol, per mmol/L	1.01	(0.92 - 1.11)	0.83			
LDL cholesterol, per mmol/L	1.03	(0.92 - 1.15)	0.59			
HDL cholesterol, per mmol/L	0.69	(0.52 - 0.92)	0.010			
Triglycerides, per mmol/L	1.04	(0.95 - 1.13)	0.40			
Oxidised LDL cholesterol, per 10 U/L	1.06	(0.99 - 1.14)	0.085			

Apolipoprotein B /Apolipoprotein A1 ratio, per unit	1.91	(1.32 - 2.76)	0.001	1.66	(1.11 - 2.49)	0.014
Beta blocker, y/n	1.20	(0.98 - 1.47)	0.082			
ACEi or ARB, y/n	1.12	(0.91 - 1.37)	0.29			
Dialysis vintage, per year	0.98	(0.96 - 1.01)	0.27			
Dialysis time per week, per hour	1.06	(1.01 - 1.12)	0.033			
Kt/V midweek session, per unit	0.98	(0.69 - 1.39)	0.90			
Phosphate, per mmol/L	1.18	(0.98 - 1.41)	0.081	1.28	(1.06 - 1.55)	0.010
Calcium, per mmol/L	0.69	(0.43 - 1.10)	0.11			
Haematocrit, per %	4.07	(0.48 - 34.5)	0.20			
Haemoglobin, per g/dL	1.04	(0.97 - 1.12)	0.23			
Albumin, per g/L	0.95	(0.92 - 0.98)	<0.001			
High sensitive C-reactive protein, per mg/L	1.17	(1.08 - 1.27)	<0.001	1.12	(1.03 - 1.22)	0.009
Sevelamer, y/n	0.86	(0.66 - 1.21)	0.26			

LDL: low densitiy lipoprotein. HDL: high density lipoprotein. ACEi: angiotensin converting enzyme inhibitor. ARB: angiotensin II receptor blocker. The significant predictors assessed by a stepwise multivariable Cox regression analysis (which originally included all variables with P<0.1 in univariate analysis) are listed.

Table 6. Univariate and multivariable adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for ischaemic stroke (116 events).

		Univariate models			Multivariable model		
		HR	95% CI	P value	HR	95% CI	P value
Sex, male		0.97	(0.67 - 1.40)	0.86			
Age, per 5 years		1.21	(1.08 - 1.34)	0.001	1.15	(1.03 - 1.29)	0.013
Region				0.55			
	Western Europe	1.47	(0.80 - 2.71)	0.22			
	Eastern Europe	1.24	(0.62 - 2.48)	0.55			
	Asia	NA					
	South-America	0.92	(0.38 - 2.18)	0.84			
	Other	Ref.					
Allocation rosuvastatin vs. placebo, y/n		1.07	(0.75 - 1.54)	0.71			
Systolic blood pressure, per 10 mm Hg		1.04	(0.96 - 1.12)	0.31			
Diastolic blood pressure, per 5 mm Hg		1.02	(0.95 - 1.09)	0.64			
Pulse pressure, per 5 mm Hg		1.03	(0.98 - 1.07)	0.33			
Body weight, per 5 kg		1.02	(0.96 - 1.08)	0.54			
Body height, per 5 cm		1.02	(0.93 - 1.13)	0.65			
Body mass index, per kg/m^2		1.01	(0.97 - 1.05)	0.66			
Current smoking, y/n		1.44	(0.92 - 2.26)	0.11			
Previous coronary heart disease, y/n		1.62	(1.12 - 2.35)	0.011			
Previous cardiovascular disease, y/n		1.73	(1.20 - 2.49)	0.003			
Diabetes, y/n		1.68	(1.14 - 2.47)	0.009			
Cholesterol, per mmol/L		1.00	(0.85 - 1.19)	0.97			
LDL cholesterol, per mmol/L		1.01	(0.83 - 1.24)	0.92			
HDL cholesterol, per mmol/L		1.18	(0.76 - 1.82)	0.46			
Triglycerides, per mmol/L		0.94	(0.79 - 1.13)	0.52			
Oxidised LDL cholesterol, per 10 U/L		1.10	(0.98 - 1.24)	0.11			

Apolipoprotein B /Apolipoprotein A1 ratio, per unit	1.09	(0.52 - 2.26)	0.83			
Beta blocker, y/n	1.07	(0.74 - 1.56)	0.71			
ACEi or ARB, y/n	1.09	(0.75 - 1.58)	0.66			
Dialysis vintage, per year	1.03	(0.99 - 1.07)	0.22			
Dialysis time per week, per hour	1.07	(0.97 - 1.18)	0.18			
Kt/V midweek session, per unit	0.70	(0.36 - 1.37)	0.30			
Phosphate, per mmol/L	0.94	(0.66 - 1.33)	0.73			
Calcium, per mmol/L	0.82	(0.35 - 1.90)	0.64			
Haematocrit, per %	1.66	(0.03 - 80.3)	0.80			
Haemoglobin, per g/dL	1.03	(0.91 - 1.16)	0.65			
Albumin, per g/L	0.89	(0.85 - 0.94)	<0.001	0.91	(0.86 - 0.96)	<0.001
High sensitive C-reactive protein, per mg/L	1.11	(0.95 - 1.29)	0.20			
Sevelamer, y/n	0.94	(0.59 - 1.52)	0.81			

LDL: low densitiy lipoprotein. HDL: high density lipoprotein. ACEi: angiotensin converting enzyme inhibitor. ARB: angiotensin II receptor blocker. The significant predictors assessed by a stepwise multivariable Cox regression analysis (which originally included all variables with P<0.1 in univariate analysis) are listed. NA: Not applicable due to low number of events.

Table 7. Univariate and multivariable adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for death from peripheral atherosclerotic disease (50 events).

	Univariate models			Multivariable model		
	HR	**95% CI**	**P value**	**HR**	**95% CI**	**P value**
Sex, male	1.00	(0.56 - 1.77)	1.00			
Age, per 5 years	1.52	(1.27 - 1.82)	<0.001	1.38	(1.14 - 1.68)	0.001
Region			0.64			
Western Europe	2.54	(0.77 - 8.31)	0.13			
Eastern Europe	2.51	(0.71 - 8.89)	0.15			
Asia	NA					
South-America	2.02	(0.48 - 8.50)	0.34			
Other	Ref.					
Allocation rosuvastatin vs. placebo, y/n	1.27	(0.73 - 2.23)	0.40			
Systolic blood pressure, per 10 mm Hg	1.01	(0.90 - 1.14)	0.84			
Diastolic blood pressure, per 5 mm Hg	0.90	(0.80 - 1.01)	0.056			
Pulse pressure, per 5 mm Hg	1.05	(0.99 - 1.13)	0.14			
Body weight, per 5 kg	1.03	(0.95 - 1.13)	0.50			
Body height, per 5 cm	0.99	(0.85 - 1.14)	0.84			
Body mass index, per kg/m^2	1.03	(0.97 - 1.08)	0.37			
Current smoking, y/n	1.04	(0.50 - 2.22)	0.92			
Previous coronary heart disease, y/n	13.04	(4.69 - 36.25)	<0.001			
Previous cardiovascular disease, y/n	7.18	(3.59 - 14.36)	<0.001	4.34	(2.11 - 8.89)	<0.001
Diabetes, y/n	3.55	(2.03 - 6.18)	<0.001	3.16	(1.77 - 5.65)	<0.001
Cholesterol, per mmol/L	1.26	(1.00 - 1.59)	0.054			
LDL cholesterol, per mmol/L	1.39	(1.05 - 1.83)	0.020	1.33	(1.03 - 1.72)	0.029
HDL cholesterol, per mmol/L	0.58	(0.26 - 1.30)	0.19			
Triglycerides, per mmol/L	1.10	(0.91 - 1.34)	0.34			
Oxidised LDL cholesterol, per 10 U/L	1.18	(1.00 - 1.40)	0.052			

Apolipoprotein B /Apolipoprotein A1 ratio, per unit	2.97	(1.23 - 7.18)	0.016			
Beta blocker, y/n	0.77	(0.42 - 1.39)	0.38			
ACEi or ARB, y/n	0.61	(0.32 - 1.15)	0.12			
Dialysis vintage, per year	0.98	(0.90 - 1.06)	0.56			
Dialysis time per week, per hour	0.97	(0.83 - 1.14)	0.75			
Kt/V midweek session, per unit	0.41	(0.14 - 1.18)	0.096			
Phosphate, per mmol/L	1.92	(1.23 - 3.02)	0.004	2.37	(1.50 - 3.75)	<0.001
Calcium, per mmol/L	1.29	(0.37 - 4.57)	0.69			
Haematocrit, per %	0.44	(0.00 - 168.1)	0.79			
Haemoglobin, per g/dL	0.97	(0.81 - 1.16)	0.76			
Albumin, per g/L	0.87	(0.81 - 0.94)	0.001	0.92	(0.84 - 1.00)	0.048
High sensitive C-reactive protein, per mg/L	1.50	(1.24 - 1.81)	<0.001	1.39	(1.12 - 1.72)	0.003
Sevelamer, y/n	0.47	(0.19 - 1.19)	0.11			

LDL: low densitiy lipoprotein. HDL: high density lipoprotein. ACEi: angiotensin converting enzyme inhibitor. ARB: angiotensin II receptor blocker. The significant predictors assessed by a stepwise multivariable Cox regression analysis (which originally included all variables with P<0.1 in univariate analysis) are listed. NA: Not applicable due to low number of events.

Figure 1. Kaplan-Meier survival curves for the new atherosclerotic endpoint in the two treatment allocation groups (rosuvastatin vs. placebo).